FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114865501> ?p ?o ?g. }

• W2114865501 abstract "The aim of the study was to evaluate the activity of a combination of doxorubicin (Dox), paclitaxel (Pacl) and 5-fluorouracil (5-FU), to define the most effective schedule, and to investigate the mechanisms of action in human breast cancer cells.The study was performed on MCF-7 and BRC-230 cell lines. The cytotoxic activity was evaluated by sulphorhodamine B assay and the type of drug interaction was assessed by the median effect principle. Cell cycle perturbation and apoptosis were evaluated by flow cytometry, and apoptosis-related marker (p53, bcl-2, bax, p21), caspase and thymidylate synthase (TS) expression were assessed by western blot.5-FU, used as a single agent, exerted a low cytotoxic activity in both cell lines. The Dox-->Pacl sequence produced a synergistic cytocidal effect and enhanced the efficacy of subsequent exposure to 5-FU in both cell lines. Specifically, the Dox-->Pacl sequence blocked cells in the G2-M phase, and the addition of 5-FU forced the cells to progress through the cell cycle or killed them. Furthermore, Dox-->Pacl pretreatment produced a significant reduction in basal TS expression in both cell lines, probably favoring the increase in 5-FU activity. The sequence Dox-->Pacl-->48-h washout-->5-FU produced a synergistic and highly schedule-dependent interaction (combination index < 1), resulting in an induction of apoptosis in both experimental models regardless of hormonal, p53, bcl-2 or bax status. Apoptosis in MCF-7 cells was induced through caspase-9 activation and anti-apoptosis-inducing factor hyperexpression. In the BRC-230 cell line, the apoptotic process was triggered only by a caspase-dependent mechanism. In particular, at the end of the three-drug treatment, caspase-8 activation triggered downstream executioner caspase-3 and, to a lesser degree, caspase-7.In our experimental models, characterized by different biomolecular profiles representing the different biology of human breast cancers, the schedule Dox-->Pacl-->48-h washout-->5-FU was highly active and schedule-dependent and has recently been used to plan a phase I/II clinical protocol." @default.
• W2114865501 created "2016-06-24" @default.
• W2114865501 creator A5013470739 @default.
• W2114865501 creator A5035580064 @default.
• W2114865501 creator A5036472378 @default.
• W2114865501 creator A5041429584 @default.
• W2114865501 creator A5047952050 @default.
• W2114865501 creator A5048641218 @default.
• W2114865501 creator A5051400852 @default.
• W2114865501 creator A5057896638 @default.
• W2114865501 creator A5058164461 @default.
• W2114865501 creator A5069404153 @default.
• W2114865501 creator A5075055655 @default.
• W2114865501 date "2005-06-22" @default.
• W2114865501 modified "2023-10-07" @default.
• W2114865501 title "Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines" @default.
• W2114865501 cites W1262485082 @default.
• W2114865501 cites W1558532670 @default.
• W2114865501 cites W1966405524 @default.
• W2114865501 cites W1970736880 @default.
• W2114865501 cites W1973540793 @default.
• W2114865501 cites W1984431867 @default.
• W2114865501 cites W2009599943 @default.
• W2114865501 cites W2016364483 @default.
• W2114865501 cites W2037827452 @default.
• W2114865501 cites W2038033520 @default.
• W2114865501 cites W2041173222 @default.
• W2114865501 cites W2058414094 @default.
• W2114865501 cites W2060932390 @default.
• W2114865501 cites W2077296023 @default.
• W2114865501 cites W2077945404 @default.
• W2114865501 cites W2080673878 @default.
• W2114865501 cites W2109689528 @default.
• W2114865501 cites W2114840421 @default.
• W2114865501 cites W2143653625 @default.
• W2114865501 cites W2148809873 @default.
• W2114865501 cites W2155611965 @default.
• W2114865501 cites W2167853394 @default.
• W2114865501 cites W2211647308 @default.
• W2114865501 cites W2232368099 @default.
• W2114865501 cites W2264804432 @default.
• W2114865501 cites W2412872181 @default.
• W2114865501 cites W2417287987 @default.
• W2114865501 cites W2473922399 @default.
• W2114865501 cites W2597616474 @default.
• W2114865501 cites W26253050 @default.
• W2114865501 cites W52461205 @default.
• W2114865501 cites W595222110 @default.
• W2114865501 cites W2395366417 @default.
• W2114865501 doi "https://doi.org/10.1186/bcr1274" @default.
• W2114865501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1242133" @default.
• W2114865501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16168113" @default.
• W2114865501 hasPublicationYear "2005" @default.
• W2114865501 type Work @default.
• W2114865501 sameAs 2114865501 @default.
• W2114865501 citedByCount "65" @default.
• W2114865501 countsByYear W21148655012012 @default.
• W2114865501 countsByYear W21148655012013 @default.
• W2114865501 countsByYear W21148655012014 @default.
• W2114865501 countsByYear W21148655012015 @default.
• W2114865501 countsByYear W21148655012016 @default.
• W2114865501 countsByYear W21148655012017 @default.
• W2114865501 countsByYear W21148655012018 @default.
• W2114865501 countsByYear W21148655012019 @default.
• W2114865501 countsByYear W21148655012020 @default.
• W2114865501 countsByYear W21148655012021 @default.
• W2114865501 countsByYear W21148655012022 @default.
• W2114865501 countsByYear W21148655012023 @default.
• W2114865501 crossrefType "journal-article" @default.
• W2114865501 hasAuthorship W2114865501A5013470739 @default.
• W2114865501 hasAuthorship W2114865501A5035580064 @default.
• W2114865501 hasAuthorship W2114865501A5036472378 @default.
• W2114865501 hasAuthorship W2114865501A5041429584 @default.
• W2114865501 hasAuthorship W2114865501A5047952050 @default.
• W2114865501 hasAuthorship W2114865501A5048641218 @default.
• W2114865501 hasAuthorship W2114865501A5051400852 @default.
• W2114865501 hasAuthorship W2114865501A5057896638 @default.
• W2114865501 hasAuthorship W2114865501A5058164461 @default.
• W2114865501 hasAuthorship W2114865501A5069404153 @default.
• W2114865501 hasAuthorship W2114865501A5075055655 @default.
• W2114865501 hasBestOaLocation W21148655011 @default.
• W2114865501 hasConcept C121608353 @default.
• W2114865501 hasConcept C123321153 @default.
• W2114865501 hasConcept C126322002 @default.
• W2114865501 hasConcept C153911025 @default.
• W2114865501 hasConcept C154317977 @default.
• W2114865501 hasConcept C185592680 @default.
• W2114865501 hasConcept C190283241 @default.
• W2114865501 hasConcept C202751555 @default.
• W2114865501 hasConcept C2776694085 @default.
• W2114865501 hasConcept C2777292972 @default.
• W2114865501 hasConcept C2780456651 @default.
• W2114865501 hasConcept C2781303535 @default.
• W2114865501 hasConcept C29537977 @default.
• W2114865501 hasConcept C502942594 @default.
• W2114865501 hasConcept C54355233 @default.
• W2114865501 hasConcept C553184892 @default.
• W2114865501 hasConcept C55493867 @default.
• W2114865501 hasConcept C71924100 @default.
• W2114865501 hasConcept C81885089 @default.

• next